Michael R. Hayden, a seasoned biotech director at Ionis Pharmaceuticals, just dumped over $1 million into company stock—buying 20,000 shares to bring his total stake to nearly 80,000. With deep expertise in drug development and R&D leadership, his bold move signals serious confidence in Ionis’s future, especially as the company navigates losses while building a strong pipeline of RNA therapies for rare diseases. This insider bet? It’s a major bullish cue for investors watching the market.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
